Article ID Journal Published Year Pages File Type
2082640 Drug Discovery Today: Technologies 2013 13 Pages PDF
Abstract

Mechanism-based inactivation (MBI) often involves metabolic bioactivation of the xenobiotic by cytochrome P450s (CYPs) to an electrophilic reactive intermediate and results in quasi-irreversible or irreversible inactivation. Such reactive intermediate can cause quasi-irreversible inhibition through coordination to the ferrous state, Fe(II), of the P450 enzyme forming a tight noncovalent bond leading to the formation of metabolic-intermediate complex (MIC). By contrast, irreversible inactivation is one of the most common causes for the observed drug–drug interaction (DDI) and usually implies the formation of a covalent bond between the metabolite and the enzyme via alkylation of either the heme or the P450 apoprotein. Here we illustrate the important points of the current literature understanding of the mechanisms of inhibition of CYP enzymes with emphasis on general mechanistic aspects of MBI for some drugs/moieties associated with the phenomenon. Additionally, the utility of computational and in silico approaches to address bioactivation issues will be briefly discussed.

Graphical abstractBioactivation of the methylenedioxy portion of paxil to the carbene reactive intermediate and subsequent quasi-irreversible inactivation of P450 enzymes via metabolic-intermediate complex (MIC).Figure optionsDownload full-size imageDownload high-quality image (86 K)Download as PowerPoint slide

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Biotechnology
Authors
, ,